Grove Biopharma
$36.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Grove Biopharma is currently valued at $64.0M as of April 23, 2025. The company has raised a total of $44.0M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.45x, Grove Biopharma has achieved a valuation that is 1.45 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Grove Biopharma's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Grove Biopharma Worth in 2025?
As of 2025, Grove Biopharma is valued at $64.0M, based on the company's Later Stage VC funding round in April 23, 2025. This valuation positions Grove Biopharma as one of the leading private companies in the sector.
Grove Biopharma Valuation History
Grove Biopharma's funding history demonstrates steady growth and investor confidence.
How Grove Biopharma Valuation is Determined
Private company valuations like Grove Biopharma's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Grove Biopharma Valuation FAQs
Is Grove Biopharma profitable?
Grove Biopharma has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Grove Biopharma's valuation compare to competitors?
Grove Biopharma is valued at $64.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Grove Biopharma IPO?
Grove Biopharma has not announced plans for an initial public offering. Until an IPO, investors can access Grove Biopharma shares through secondary market platforms.